Assessing a Beta-Lactam Allergy Removal Program to Improve Antibiotic Use in Patients with Blood Cancers

What this Trial Is About

Researchers are evaluating the impact of a beta-lactam allergy delabeling intervention on antibiotic use and clinical outcomes in patients hospitalized with hematologic malignancies such as lymphoma, leukemia, and myeloma. These patients often face infection-related risks but may have limited antibiotic options due to self-reported beta-lactam allergies. Since many reported allergies are not true allergies, this study aims to assess a pharmacist-led intervention specifically for this vulnerable group. The intervention involves a multi-step process led by a clinical pharmacist who assesses each participants beta-lactam allergy history using the RENEW-IN algorithm. Participants may undergo additional allergy testing based on the assessment. If appropriate, their allergy label is removed from their electronic medical record, potentially improving access to beta-lactam antibiotics. The study compares patients actively participating in this intervention to a control group of similar patients hospitalized before the intervention was introduced. Participants will be monitored from enrollment through their hospitalization, with data collected on antibiotic use, hospital length of stay, and clinical outcomes related to infections and intensive care needs for up to 36 months. Researchers will review electronic medical records to track antibiotic days of therapy, infection rates, ICU transfers, and patient disposition. This extended follow-up allows evaluation of the long-term effects of the allergy delabeling program on patient care and outcomes.

Allergy Delabeling in Antibiotic Stewardship - Intervention